Study of the genetic and epigenetic variability involved in the occurrence of Cannabic Hyperemesis Syndrome in chronic cannabis consumers

Cannabinoid hyperemesis syndrome (CHS) is a condition associated with chronic cannabis use, characterized by cyclic vomiting episodes often temporarily relieved by hot showers. It progresses through three phases: a prodromal phase with prolonged morning nausea without appetite loss, a hyperemetic phase marked by severe vomiting, abdominal pain, and sweating, and a recovery phase where symptoms resolve after cannabis cessation, the primary treatment.

The CANEMESE clinical study, conducted by the Poitiers University Hospital (CHU) under the coordination of Dr. Stéphanie PAIN, investigates the influence of cannabinoid concentrations and genetic variations (CYP2C9, CYP2C19, FAAH, TRPV1, CNR1, CNR2) on CHS development. The study compares two groups: « case » patients, chronic cannabis users who have developed CHS, and « control » patients, also chronic cannabis users (at least weekly) who have never experienced this syndrome.

The internship aims to expand genetic polymorphism analyses to new patients, mainly from Limoges and Poitiers, and potentially integrate an epigenetic dimension by studying DNA methylation in affected patients. These studies could help clarify the underlying mechanisms and improve CHS management. Techniques used to characterize these SNPs/variations include DNA extraction from blood samples, pyrosequencing, and the SNaPshot Multiplex method.

#Hyperemesis # DNA #Sequencing #Multiplex

Study of the genetic and epigenetic variability involved in the occurrence of Cannabic Hyperemesis Syndrome in chronic cannabis consumers

Cannabinoid hyperemesis syndrome (CHS) is a condition associated with chronic cannabis use, characterized by cyclic vomiting episodes often temporarily relieved by hot showers. It progresses through three phases: a prodromal phase with prolonged morning nausea without appetite loss, a hyperemetic phase marked by severe vomiting, abdominal pain, and sweating, and a recovery phase where symptoms resolve after cannabis cessation, the primary treatment.

The CANEMESE clinical study, conducted by the Poitiers University Hospital (CHU) under the coordination of Dr. Stéphanie PAIN, investigates the influence of cannabinoid concentrations and genetic variations (CYP2C9, CYP2C19, FAAH, TRPV1, CNR1, CNR2) on CHS development. The study compares two groups: « case » patients, chronic cannabis users who have developed CHS, and « control » patients, also chronic cannabis users (at least weekly) who have never experienced this syndrome.

The internship aims to expand genetic polymorphism analyses to new patients, mainly from Limoges and Poitiers, and potentially integrate an epigenetic dimension by studying DNA methylation in affected patients. These studies could help clarify the underlying mechanisms and improve CHS management. Techniques used to characterize these SNPs/variations include DNA extraction from blood samples, pyrosequencing, and the SNaPshot Multiplex method.

#Hyperemesis # DNA #Sequencing #Multiplex

internship supervisor

Claire-Lafay CHEBASSIER
& Stéphanie PAIN